Olena Miroshnichenko/iStock via Getty Images Last month, I published a deep dive into Zoetis' (NYSE:ZTS) business. As with any pharma company, its pipeline is critical to its future growth. Librela is expected to be one of their most successful drugs, but I believe management is heavily sandbagging its $1B peak sales target for the medication:   Management's expectation (2023 Investor Day) What Is Librela Librela is a first-of-its-kind medication targeting the treatment of Osteoarthritis (OA) in dogs, a ...